Member Info for Rooba

I must admit, I was quietly concerned that dose escalation hadn't started, as that is the main early indicator (for us) that Pre cision works in humans, not just in mice.
So, after the LFT **** show, it's a big relief today as one of those who probably invested more than I should here.

I am now invested in a company that can deliver higher doses of toxic drugs into cancer patients - and thereby save lives and make money.
That feels really good :-)

For those questioning the timing or value of presenting to II's now, I think there are a number of simple reasons:
- Avacta could do with more II investment to both boost the SP and make it less volatile.
- II's will not necessarily know everything that Avacta has to offer - some may have taken little or no interest so far.
- The failure (to date) of commercialising the LFT makes it easier to highlight that Avacta is not a 'covid stock', and focus on the theraputics.
- Companies do sales pitches all the time with no 'new' information.
- If Avacta repeat the same messages given to us re AVA6000 trials, it means so much more now 6 months along.
- The SP is an absolute steal IF Pre-cision works, and still great long term value via commercialising affimers (which we know work).

Well said.
I filtered the main culprits a few weeks ago, and find it a much better, more balanced board when the green boxes are on.

To add another point that gets missed by everybody - vaccinating millions of younger healthy people uses up an immense amount of healthcare resources.
Huge numbers of people are living in pain or dying because they cannot get medical treatment, and some of this is as a direct result of healthcare resources being directed into vaccinations.
So to argue that vaccinations protect the NHS is not strictly true. For the elderly, yes, it does. But for the young, its incredibly ineffective as it takes many 1000s of jabs to stop just 1 hospitalisation. And lets not forget, the jabs don't prevent spread.

Its scary how many people go full on fascist when it comes to covid.
Average age of death from covid is 82. Thats higher than average age of death for non covid reasons. And yet paranoia reigns supreme, because of the fear spread by governments, the media, big tech and big pharma.

Well done rxdav for bringing some sense to this conversation.

SP was 5p in January last year. So thats a 4-fold increase in less than 2 years. Hardly a "jam tomorrow' share.
As is normal, patience is needed to see more SP growth, but some just don't have any patience!

There won't be many eyes on this today due to the covid panic. So today's price won't reflect just how good today's news is.
But over the coming days and weeks I am very confident the market will react very favourably.
Sit back and enjoy the ride.

Rorkes, I think its just lost in translation a bit.
It's a 90% dose (not high) but potentially a high concentration in the tumour, which COULD be the equivalent of a high dose.

At least I think thats what is being suggested.

The madness is the obsession and paranoia about covid and lack of faith in the vaccines.

Curius - I don't think thats how he works.
He talks up stocks he's in and looking for higher returns (understandably), and goes quiet when selling. He seems more straight than many of the stock commentators.
There are plenty of people who invested here much higher and will sell based on emotion, rather than future prospects/growth.

Big Al likes to think of Avacta as being a safe firm to be invested in, and Affimers get their name from an anagram of safe firm.

Disgruntled makes a fair point.
The share sales met their tax obligations "in part", which I assume means they sold more than they needed to, to meet those obligations.
Its not a good look, especially when most of the directors sold shares at 17-19p in February.

Theres a lot of useless noise on this board lately.

Yes the SP drop is horrible, but if you knew what you were doing, you invested here because Avacta is a lot more than just an LFT company. The big short term LFT payday appears to have gone, but the long term prospects are alive and kicking, and fully funded up to and beyond critical research timelines/results. Thats an enviable position for a company like this to be in.

So if you can, sit back, relax, and wait for the SP rollercoaster to move back up to fair value over the coming months and years.

Wyn, I don't think another 10-20 million vaccinations of younger healthier people will achieve anything, other than prevent health workers caring for sick people, because they are too busy vaccinating those who don't need a vaccine.

I know if we have more people suffering with covid and extended lockdowns we make more money here, but this fearmongering is ridiculous.
The numbers of people dying from covid are tiny. We have more suicides every day, mainly in younger people, but nobody cares about continuing to damage young people's lives with these restrictions.
Covid is a seasonal virus - it will be subdued in the summer months, before going up in the winter and cause deaths in the elderly and vulnerable - just as flu always did, which never used to bother us.
Yes, covid is worse, but the vaccines change that. Also, viruses typically become less virulent over time when they mutate (you won't hear that from the mainstream media or government). They just say every new variant is 50% ish more infectious, which if you do the maths, we're supposed to now have a massively more transmissable virus than the first and 2nd waves, whilst the numbers have dwindled to almost nothing - and people sill believe this rubbish, FFS!

I'm all for making money here on the help that Avacta's LFT can bring, but the fearmongering and the welcoming of ongoing restrictions just does my head in.

Rant over!

The longer this drags on, the more inclined I am to think that MHRA registration has been confirmed and that the test is already ("immediately") on the market.
An RNS confirming registration but with a delay in commercials could actually drive the SP down, as our likely expectations when AL says immediately, is that Avacta will have deals already lined up and sell the tests immediately.
So perhaps AL would rather leave us speculating about how long "the coming days" is, rather than how long "immediately" is, and why haven't we sold anything yet.

Ophidian gave us a detailed timeline to expect a test ready last september, following a simple, 2-week tech transfer. He then went on to say that tech transfer was complete in november (because he couldn't understand the RNS).
He is an expert in telling everybody he's an expert, and there his expertise ends!

And predicting an RNS to land today, tomorrow or in the coming days requires zero expertise.

Taking Avacta out of the equation, the odd thing about this 9+ working days wait, is that the government were desperate to deliver 'operation moonshot' last year, and now they can't be bothered to rubber stamp a great UK developed test.
So the longer this goes on, the less it becomes about AL's ability to communicate timelines, and more about why the hell the UK authorities are delaying approval.
I have no theories on why they are dragging their feet, just frustrations and growing concern on why it hasn't happened yet.

Lets hope tomorrow morning the wait becomes irrelevant / worth it.

When the CE marking arrives, we'll find out how long "in the coming days" is.
But what are the odds that the commercials are not announced at the same time, and then we'll be speculating how long "immediately" is in 'Avacta time' ;-)

Beret, on the 8th March we were told to expect CE marking and commercials around the end of March. Thats a 3-week prediction - 10 weeks ago!
That then moved on to early May.
We're still waiting on 18th May.